Share This Page
Suppliers and packagers for generic pharmaceutical drug: nifurtimox
✉ Email this page to a colleague
nifurtimox
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464 | NDA | Bayer Healthcare Pharmaceuticals INC. | 50419-750-01 | 1 BOTTLE in 1 CARTON (50419-750-01) / 100 TABLET, FILM COATED in 1 BOTTLE | 2020-10-01 |
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464 | NDA | Bayer Healthcare Pharmaceuticals INC. | 50419-751-01 | 1 BOTTLE in 1 CARTON (50419-751-01) / 100 TABLET, FILM COATED in 1 BOTTLE | 2020-10-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Nifurtimox
Introduction
Nifurtimox is a pioneering antitrypanosomal medication primarily used to treat Chagas disease, a parasitic illness endemic to Latin America. Developed in the 1960s by Bayer, it has since gained global recognition, especially as a vital drug in neglected tropical disease (NTD) control programs. Critical to its distribution are the key suppliers, comprising pharmaceutical manufacturers, generic producers, and regional distributors, whose roles influence drug availability, affordability, and regulatory compliance. This article offers a comprehensive analysis of current nifurtimox suppliers, their market positioning, manufacturing capacities, and strategic significance.
Historical Background and Market Overview
Initially marketed under the brand name Lampit by Bayer, nifurtimox's supply landscape has evolved over the decades. Given its designation by the World Health Organization (WHO) as an essential medicine, its market structure comprises a limited number of producers with the capacity to meet global demand, especially for endemic regions. The increasing focus on NTDs has spurred some manufacturers to expand or diversify their portfolio, although the supply remains concentrated among a few key players.
Major Suppliers of Nifurtimox
1. Bayer AG
Overview:
Bayer remains the patent holder and original manufacturer of nifurtimox. The company historically supplied the drug under the brand name Lampit. Its global footprint, extensive research infrastructure, and regulatory expertise position Bayer as a primary supplier for parts of the market, especially in countries with procurement agreements or direct governmental procurement.
Supply Dynamics:
Although Bayer's commercial focus has shifted towards other therapeutic areas, it retains manufacturing capacity for nifurtimox, primarily for supply to WHO programs and select markets. Bayer's stringent quality standards help ensure high-purity products but limit availability in regions underserved by the company directly.
Strategic Significance:
Bayer's proprietary control over nifurtimox's patent and manufacturing pipeline underpins its central role in the global supply chain, influencing pricing and access, particularly in high-income markets.
2. Pharmaceuticals for Human Use: Sanofi, Pfizer, and Merck
Overview:
Although these multinational giants do not primarily produce nifurtimox, their research and development pipelines focus on NTDs, potentially influencing future supply options through partnerships or licensing agreements.
Potential Suppliers:
While currently not primary producers, these companies may serve as backup suppliers via licensing or technology transfer agreements, especially given increasing global health mandates and the push for affordable NTD treatments.
3. Generic Manufacturers and Regional Producers
Emerging Players:
A significant shift in nifurtimox supply sources stems from generic pharmaceutical manufacturers, especially those operating under voluntary licensing agreements or WHO prequalification programs. Their role is pivotal in expanding access in endemic regions.
-
NK Pharmaceutical (India):
According to recent reports, NK Pharmaceutical, based in India, has developed a generic nifurtimox formulation, registered in several low- and middle-income countries. Their manufacturing facilities adhere to WHO GMP standards, ensuring quality and safety. -
Cuba’s BioCubaFarma:
Cuba’s bio-pharmaceutical sector has been engaged in producing affordable NTD medications, potentially including nifurtimox under licensing arrangements, contributing to regional supply. -
China-based Manufacturers:
Emerging Chinese generic producers are building manufacturing capacities, often through partnerships or licensing arrangements with original patent holders, to supply nifurtimox at reduced costs.
Licensing and Prequalification Efforts:
The WHO’s prequalification process encourages generic manufacturing, boosting supply in endemic regions. Notable efforts include licensing agreements with the Drugs for Neglected Disease initiative (DNDi) and similar organizations to facilitate local manufacturing and improve access.
Regulatory and Supply Chain Considerations
Regulatory Approvals:
Manufacturers must secure approvals from agencies such as the U.S. FDA, EMA, or WHO prequalification to ensure quality standards meet international benchmarks. Registration processes often influence the supply chain’s robustness.
Supply Chain Challenges:
Manufacturing complexity, low profit margins, and a limited commercial market inherently restrict the number of suppliers. These factors contribute to potential shortages during global health crises or supply chain disruptions.
Patent Expirations and Generic Entry:
Bayer’s patent expiry has opened pathways for generics, but patent stabilization or new formulations may impact future competition and supply stability.
Emerging Trends and Future Outlook
-
Increased Local Production:
Government and NGO initiatives are encouraging local manufacturing in endemic regions, including Africa, India, and Latin America, to enhance supply resilience. -
Technology Transfer Agreements:
Partnerships between originator companies and generic manufacturers are fostering broader access, especially under the framework of WHO’s prequalification and licensing programs. -
Market Consolidation:
Potential for market consolidation among manufacturers to streamline supply, reduce costs, and ensure consistent quality. -
Impact of Regulatory Hurdles:
Strict compliance requirements could delay new entrants but are vital to ensuring safe and efficacious supply.
Conclusion
The supply landscape for nifurtimox is characterized by a mixture of originator, generic, and regional manufacturers. Bayer remains a key driver due to its historical patent rights, but the expanding role of generic producers—especially in India and China—is critical in increasing access, particularly in endemic territories. Regional manufacturing capacity, coupled with strategic licensing and WHO prequalification programs, promises a more resilient supply chain moving forward, crucial for controlling and eventually eliminating Chagas disease.
Key Takeaways
- Limited but Strategic Supply Chain: The nifurtimox market is concentrated among few suppliers, predominantly Bayer, with emerging generic producers playing an increasing role.
- Licensing and Prequalification Drive Access: WHO initiatives facilitate market entry for generics, expanding availability in high-burden regions.
- Regional Manufacturing Is Critical: Local production capabilities in endemic countries improve supply resilience and reduce dependency on imports.
- Regulatory Compliance Is Key: Stringent standards ensure quality but can pose barriers for new entrants.
- Future Growth Hinges on Partnerships: Collaborations and technology transfer will shape the supply landscape, impacting global access.
FAQs
1. Who is the primary manufacturer of nifurtimox globally?
Bayer AG is the original patent holder and primary supplier of nifurtimox, especially in high-income markets and for WHO programs.
2. Are there generic alternatives to Bayer’s nifurtimox?
Yes, several generic manufacturers, predominantly in India and China, produce nifurtimox under licensing agreements, contributing to increased access in endemic regions.
3. How does WHO facilitate nifurtimox supply?
The WHO prequalifies manufacturers and facilitates licensing agreements, encouraging production of affordable, quality-assured nifurtimox for global use.
4. What are the challenges to expanding nifurtimox supply?
Limited number of manufacturers, complex regulatory requirements, low profit margins, and patent exclusivity are primary barriers.
5. How might future supply stability be enhanced?
Through increased local manufacturing, strategic licensing, technological transfer, and strengthening regional supply chains to reduce dependency on single sources.
References
[1] World Health Organization. "Nifurtimox for Chagas disease." WHO Essential Medicines List. 2021.
[2] Bayer AG. "Nifurtimox product information." Bayer Pharmaceuticals, 2022.
[3] Drugs for Neglected Diseases Initiative (DNDi). "Access and licensing agreements for NTD medicines." 2022.
[4] Indian Pharmacopoeia Commission. "Guidelines for manufacturing generic antitrypanosomal drugs." 2021.
More… ↓
